ATE526330T1 - Heterotrizyklische verbindungen als antagonisten des crf-rezeptors - Google Patents

Heterotrizyklische verbindungen als antagonisten des crf-rezeptors

Info

Publication number: ATE526330T1
Authority: AT; Austria
Prior art keywords: ring; nitrogen; formula; antagonists; heterocyclic
Prior art date: 2000-12-28

Application number

AT07111569T

Other languages

English (en)

Inventor

Hisao Nakai

Yoshifumi Kagamiishi

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-28

Filing date

2001-12-27

Publication date

2011-10-15

2001-12-27 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526330T1 publication Critical patent/ATE526330T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
125000002837 carbocyclic group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
208000007848 Alcoholism Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 1
102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 abstract 1
208000020401 Depressive disease Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000008469 Peptic Ulcer Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
208000011906 peptic ulcer disease Diseases 0.000 abstract 1
208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Immunology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)

AT07111569T 2000-12-28 2001-12-27 Heterotrizyklische verbindungen als antagonisten des crf-rezeptors ATE526330T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2000402517		2000-12-28

Publications (1)

Publication Number	Publication Date
ATE526330T1 true ATE526330T1 (de)	2011-10-15

Family

ID=18866787

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01995808T ATE375345T1 (de)	2000-12-28	2001-12-27	Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist
AT07111569T ATE526330T1 (de)	2000-12-28	2001-12-27	Heterotrizyklische verbindungen als antagonisten des crf-rezeptors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT01995808T ATE375345T1 (de)	2000-12-28	2001-12-27	Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist

Country Status (24)

Country	Link
US (3)	US7034153B2 (de)
EP (2)	EP1354884B1 (de)
JP (2)	JP3528968B2 (de)
KR (1)	KR100843281B1 (de)
CN (2)	CN1274690C (de)
AT (2)	ATE375345T1 (de)
AU (1)	AU2002226674B2 (de)
BR (1)	BR0116609A (de)
CA (1)	CA2432148C (de)
CZ (1)	CZ20031777A3 (de)
DE (1)	DE60130924T2 (de)
DK (1)	DK1354884T3 (de)
ES (2)	ES2294047T3 (de)
HU (1)	HUP0303653A3 (de)
IL (2)	IL156609A0 (de)
MX (1)	MXPA03005913A (de)
NO (1)	NO326522B1 (de)
NZ (1)	NZ526712A (de)
PL (1)	PL363381A1 (de)
PT (1)	PT1354884E (de)
RU (1)	RU2291869C2 (de)
TW (1)	TWI293630B (de)
WO (1)	WO2002053565A1 (de)
ZA (1)	ZA200305003B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6562965B1 (en) *	2000-07-06	2003-05-13	Bristol-Myers Squibb Pharma Company	Convergent synthesis of α-aryl-β-ketonitriles
ES2294047T3 (es) *	2000-12-28	2008-04-01	Ono Pharmaceutical Co., Ltd.	Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
UA80295C2 (en) *	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
WO2004113300A1 (ja) *	2003-06-23	2004-12-29	Ono Pharmaceutical Co., Ltd.	新規三環性複素環化合物
ATE478873T1 (de)	2003-06-25	2010-09-15	Ono Pharmaceutical Co	Methansulfonsäuresalz einer pyrazolopyrimidinverbindung, kristall davon und verfahren zu deren herstellung
WO2005061508A1 (ja) *	2003-12-22	2005-07-07	Ono Pharmaceutical Co., Ltd.	三環式複素環化合物およびその化合物を有効成分とする医薬
WO2005087775A1 (ja) *	2004-03-15	2005-09-22	Ono Pharmaceutical Co., Ltd.	三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
DK1773345T3 (en) *	2004-06-30	2014-03-24	Athersys Inc	NON-imidazol-tertiary amines AS HISTAMINE-3 receptor inhibitors in treating cognitive disorders, sleep disorders, obesity and other CNS DISORDERS
EP1771169A1 (de)	2004-07-14	2007-04-11	PTC Therapeutics, Inc.	Verfahren zur behandlung von hepatitis c
US7868037B2 (en)	2004-07-14	2011-01-11	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
JP2008507518A (ja)	2004-07-22	2008-03-13	ピーティーシーセラピューティクス，インコーポレーテッド	Ｃ型肝炎を治療するためのチエノピリジン
AR051780A1 (es) *	2004-11-29	2007-02-07	Japan Tobacco Inc	Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
ES2459742T3 (es)	2004-12-22	2014-05-12	Ono Pharmaceutical Co., Ltd.	Compuesto tricíclico y uso del mismo
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
NZ587215A (en) *	2008-01-22	2012-08-31	Takeda Pharmaceutical	Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
WO2009093208A2 (ru) *	2008-01-24	2009-07-30	Alla Chem, Llc	ЗАМЕЩЕННЫЕ 2-AMИHO-3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2369600C1 (ru) *	2008-01-24	2009-10-10	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU2376291C1 (ru) *	2008-05-07	2009-12-20	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 3,5-ДИАМИНО-4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN103249735B (zh) *	2010-07-22	2016-04-06	扎夫根股份有限公司	三环化合物及其制备和使用方法
US8927562B2 (en)	2010-09-28	2015-01-06	Merck Sharp & Dohme Corp.	Fused tricyclic inhibitors of mammalian target of rapamycin
WO2012047569A1 (en) *	2010-09-28	2012-04-12	Schering Corporation	Fused tricyclic inhibitors of mammalian target of rapamycin
HRP20171859T1 (hr) *	2010-12-17	2018-01-26	Reata Pharmaceuticals, Inc.	Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
PT2760453T (pt)	2011-09-30	2016-08-02	Ipsen Pharma Sas	Inibidores macrocíclicos da cinase lrrk2
KR20170048599A (ko)	2014-09-17	2017-05-08	온코디자인 에스.에이.	거대 고리 ｌｒｒｋ2 키아나제 저해제
US11220510B2 (en)	2018-04-09	2022-01-11	Incyte Corporation	Pyrrole tricyclic compounds as A2A / A2B inhibitors
EP4069700B1 (de) *	2019-12-03	2024-07-03	Turning Point Therapeutics, Inc.	Makrocyclen zur verwendung beim behandeln von krankheiten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5420128A (en)	1990-10-09	1995-05-30	Otsuka Pharmaceutical Co., Ltd.	Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor
AU707530B2 (en) *	1995-09-28	1999-07-15	Otsuka Pharmaceutical Factory, Inc.	Analgesic composition
TR199900389T2 (xx)	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
US6194574B1 (en)	1998-06-09	2001-02-27	Neurogen Corporation	Pyrido[2,3-b]indolizine derivatives and aza analogues thereof: CRF1 specific ligands
DK1129096T3 (da)	1998-11-12	2003-09-15	Neurocrine Biosciences Inc	CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
ES2180338T3 (es)	1998-11-12	2003-02-01	Neurocrine Biosciences Inc	Antagonistas del receptor de crf y metodos relacionados.
ES2294047T3 (es) *	2000-12-28	2008-04-01	Ono Pharmaceutical Co., Ltd.	Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.

2001
- 2001-12-27 ES ES01995808T patent/ES2294047T3/es not_active Expired - Lifetime
- 2001-12-27 HU HU0303653A patent/HUP0303653A3/hu unknown
- 2001-12-27 BR BR0116609-3A patent/BR0116609A/pt not_active Application Discontinuation
- 2001-12-27 DK DK01995808T patent/DK1354884T3/da active
- 2001-12-27 AT AT01995808T patent/ATE375345T1/de active
- 2001-12-27 CA CA2432148A patent/CA2432148C/en not_active Expired - Fee Related
- 2001-12-27 US US10/250,328 patent/US7034153B2/en not_active Expired - Fee Related
- 2001-12-27 KR KR1020037008815A patent/KR100843281B1/ko not_active Expired - Fee Related
- 2001-12-27 DE DE60130924T patent/DE60130924T2/de not_active Expired - Lifetime
- 2001-12-27 WO PCT/JP2001/011581 patent/WO2002053565A1/ja not_active Ceased
- 2001-12-27 AU AU2002226674A patent/AU2002226674B2/en not_active Ceased
- 2001-12-27 JP JP2002555088A patent/JP3528968B2/ja not_active Expired - Fee Related
- 2001-12-27 EP EP01995808A patent/EP1354884B1/de not_active Expired - Lifetime
- 2001-12-27 CZ CZ20031777A patent/CZ20031777A3/cs unknown
- 2001-12-27 RU RU2003119138/04A patent/RU2291869C2/ru not_active IP Right Cessation
- 2001-12-27 EP EP07111569A patent/EP1832590B8/de not_active Expired - Lifetime
- 2001-12-27 AT AT07111569T patent/ATE526330T1/de not_active IP Right Cessation
- 2001-12-27 IL IL15660901A patent/IL156609A0/xx unknown
- 2001-12-27 MX MXPA03005913A patent/MXPA03005913A/es active IP Right Grant
- 2001-12-27 PL PL01363381A patent/PL363381A1/xx unknown
- 2001-12-27 CN CNB018227201A patent/CN1274690C/zh not_active Expired - Fee Related
- 2001-12-27 ES ES07111569T patent/ES2369837T3/es not_active Expired - Lifetime
- 2001-12-27 CN CNA2006101061544A patent/CN1896076A/zh active Pending
- 2001-12-27 NZ NZ526712A patent/NZ526712A/en unknown
- 2001-12-27 PT PT01995808T patent/PT1354884E/pt unknown
- 2001-12-28 TW TW090132698A patent/TWI293630B/zh not_active IP Right Cessation
2003
- 2003-06-24 IL IL156609A patent/IL156609A/en not_active IP Right Cessation
- 2003-06-26 NO NO20032956A patent/NO326522B1/no not_active IP Right Cessation
- 2003-06-26 ZA ZA2003/05003A patent/ZA200305003B/en unknown
- 2003-12-05 JP JP2003406938A patent/JP4217968B2/ja not_active Expired - Fee Related
2005
- 2005-09-07 US US11/219,736 patent/US7459459B2/en not_active Expired - Fee Related
2008
- 2008-09-02 US US12/202,984 patent/US7807688B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60130924T2 (de)	2008-07-17
EP1832590A3 (de)	2007-11-14
JPWO2002053565A1 (ja)	2004-05-13
JP2004083597A (ja)	2004-03-18
HUP0303653A2 (hu)	2004-03-01
NO20032956D0 (no)	2003-06-26
AU2002226674B2 (en)	2007-03-22
US7807688B2 (en)	2010-10-05
CZ20031777A3 (cs)	2003-10-15
ATE375345T1 (de)	2007-10-15
KR100843281B1 (ko)	2008-07-09
NO20032956L (no)	2003-08-28
TWI293630B (en)	2008-02-21
WO2002053565A1 (en)	2002-07-11
IL156609A0 (en)	2004-01-04
EP1832590B1 (de)	2011-09-28
EP1354884A4 (de)	2005-09-07
EP1354884B1 (de)	2007-10-10
EP1832590B8 (de)	2012-04-25
CA2432148C (en)	2011-01-18
PT1354884E (pt)	2007-12-24
BR0116609A (pt)	2005-02-15
NO326522B1 (no)	2008-12-22
CA2432148A1 (en)	2002-07-11
JP4217968B2 (ja)	2009-02-04
MXPA03005913A (es)	2005-04-19
ZA200305003B (en)	2005-07-27
DE60130924D1 (de)	2007-11-22
KR20030070593A (ko)	2003-08-30
PL363381A1 (en)	2004-11-15
ES2294047T3 (es)	2008-04-01
CN1491225A (zh)	2004-04-21
CN1896076A (zh)	2007-01-17
ES2369837T3 (es)	2011-12-07
IL156609A (en)	2010-02-17
US20040072833A1 (en)	2004-04-15
EP1354884A1 (de)	2003-10-22
US7459459B2 (en)	2008-12-02
DK1354884T3 (da)	2008-03-03
EP1832590A2 (de)	2007-09-12
NZ526712A (en)	2005-03-24
US7034153B2 (en)	2006-04-25
CN1274690C (zh)	2006-09-13
RU2291869C2 (ru)	2007-01-20
JP3528968B2 (ja)	2004-05-24
US20060122392A1 (en)	2006-06-08
HUP0303653A3 (en)	2006-05-29
US20090137604A1 (en)	2009-05-28

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60130924D1 (de)	2007-11-22	Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist
HUP0102187A2 (hu)	2001-11-28	Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
ATE247654T1 (de)	2003-09-15	Neue heterozyklische verbindungen
DE60234812D1 (de)	2010-02-04	Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
NO175259C (no)	1994-09-21	Analogifremgangsmåte for fremstilling av terapeutisk aktive triazolo-1,4-diazepinforbindelser
NO20022442D0 (no)	2002-05-23	Legemidler for sykdommer i forbindelse med reduksjon i benmasse
HU9403098D0 (en)	1994-12-28	1-piperazino-1,2-dihydroindene derivatives and pharmaceutical compositions containing them
ATE186301T1 (de)	1999-11-15	An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
ATE478048T1 (de)	2010-09-15	Pharmazeutisch aktive benzsulfonamidderivate als inhibitoren von protein-jun-kinasen
KR890014522A (ko)	1989-10-24	사이클릭 이미드의 아릴피페라지닐알콕시 유도체, 이의 제조방법 및 약제로서의 이의 용도
DE60112725D1 (de)	2005-09-22	Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
DE69409611D1 (de)	1998-05-20	Dithiocarbonimidderivate als Fungizide, Insektizide und Akarizide
EP1134216A4 (de)	2002-01-30	Mittel gegen medikamentenresistente bakterienstämme und anti-chlamydiamittel
ATE263183T1 (de)	2004-04-15	A-500359-derivate
ATE294780T1 (de)	2005-05-15	Arylpiperidin- und aryl-1,2,5,6- tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
EP0982029A4 (de)	2002-07-03	Vorbeugende /heilmittel fuer arteriosklerose
FR2642758B1 (fr)	1991-05-17	Derives de pyrimidine,2-(4-((alpha)-heteroaryl-(alpha) aryl-((alpha)-alkyl)-methoxy)-butyl)-1-piperazinyl), avec activite serotoninergique
ATE319452T1 (de)	2006-03-15	Arzneimittel gegen essstörungen
ATE241985T1 (de)	2003-06-15	Therapeutisches mittel zur behandlung von nierenerkrankungen
TH66457A (th)	2005-01-17	การใช้แบบใหม่
RU2000114184A (ru)	2004-02-20	Ацилированные гетероциклические производные, лекарственное средство, обладающее селективной антагонистической активностью против NK2-рецепторов, способ профилактики или лечения заболевания
TH54462A3 (th)	2002-12-17	ซัลฟานิลออกซาโซลแอมีนเป็นสารประกอบที่มีฤทธิ์เชิงรักษา